Cantor Fitzgerald lowered the firm’s price target on Vaxart to $4 from $6 and keeps an Overweight rating on the shares following the Q2 results. Vaxart had a “productive” quarter as it continues to advance its norovirus program, the key value-driver for the company given that there is currently no approved norovirus vaccine on the market, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VXRT:
- Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
- Vaxart reports Q2 EPS (16c), consensus (18c)
- Vaxart reports positive topline Phase 2 data of norovirus vaccine candidate
- Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
- Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET